Browse Articles

Discover research articles across all indexed journals

Experimentally calibrated numerical prediction of underwater vibroacoustic response of bolted and embedded composite steel joints

Scientific Reports Dajiang Wu Jul 01, 2026 DOI: 10.1038/s41598-026-51291-7

Can multispecific biologics break the efficacy ceiling?

Nature Reviews Drug Discovery Asher Mullard Jul 01, 2026 DOI: 10.1038/d41573-026-00106-5

First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA

Nature Reviews Clinical Oncology Diana Romero Jul 01, 2026 DOI: 10.1038/s41571-026-01169-4

Connecting single-cell transcriptomes to projectomes in the mouse visual cortex

Nature Staci A. Sorensen, Nathan W. Gouwens, Yun Wang et al. Jul 01, 2026 DOI: 10.1038/s41586-026-10424-8

Self‐Adaptive Charge Transfer States in Aqueous Solutions Promote Fast Intersystem Crossing in a Photosensitizer for Tumor Inhibition

Advanced Materials Ran Wang, Xiang Xia, Zongwei Zhang et al. Jul 01, 2026 DOI: 10.1002/adma.73793

ABSTRACT Although conventional design strategies of photosensitizers (PSs) have enabled control of their excited‐state evolution in organic solvents, their distinct photophysical evolution pathways in aqueous solutions severely reduce their intersystem crossing (ISC) rates and reactive oxygen species (ROS) yields. Thus, the design of high‐performance PSs with high ISC rates and ROS yields in aqueous solutions remains a challenge for photodynamic therapy (PDT). In this study, we utilized the ability of aqueous solvents to promote charge transfer to construct Cy5‐PCZ, a PS that can self‐adaptively generate charge transfer singlet states ( 1 CT) and charge transfer triplet states ( 3 CT) in aqueous solutions, thereby promoting ISC. Transient absorption spectroscopy and theoretical calculations demonstrated that the ISC time (∼5 ps) of Cy5‐PCZ was two orders of magnitude faster than Cy5 without PCZ (∼580 ps). Thus, Cy5‐PCZ exhibited markedly increased yields of both type I and type II ROS in aqueous solutions. Consequently, Cy5‐PCZ–mediated PDT induced cancer cell apoptosis and pyroptosis at low concentrations, and markedly suppressed subcutaneous tumor growth and lung metastasis in mouse models. Therefore, this study offers a rational design principle for optimizing the excited‐state processes of high‐performance PSs in aqueous media, thereby enhancing their efficacy in biological applications.

Doping Manipulation of Donor/Acceptor by Perovskite Quantum Dots Enables >20.5% Organic Nonfullerene Solar Cells

Advanced Materials Bin Li, Du Li, Xinyu Zhao et al. Jul 01, 2026 DOI: 10.1002/adma.73530

ABSTRACT Organic nonfullerene solar cells (ONSCs) have achieved remarkable progress, with power conversion efficiency (PCE) now surpassing 20%. To further improve the device performance, herein, we demonstrate a facile doping strategy using emerging perovskite quantum dots (QDs), which is anticipated to address critical issues like high exciton binding energy and limited charge transport. In a typical sequentially deposited planar heterojunction (PHJ) ONSCs, FAPbI 3 QDs were introduced into the donor polymer (D18) and acceptor molecule (L8BO) layers separately, which enables precise manipulation of the vertical doping and decouples the influence of QDs on donor/acceptor. Comprehensive characterizations reveal that the FAPbI 3 QD doping reduces energy disorder, enhances crystallinity, and promotes cascade energy alignment, thereby facilitating exciton dissociation and charge transport. Moreover, FAPbI 3 QDs act as energy mediators, prolonging carrier lifetime and suppressing non‐radiative recombination. The optimal D18/L8BO device with simultaneous doping of donor/acceptor achieves a best PCE of 20.55% with a high fill factor exceeding 82%. We also demonstrate the application of QD doping strategy in varying representative donor/acceptor systems, paving a new avenue for minimizing energy loss and advancing the efficiency of ONSCs.

Self‐Powered Flexible Triboelectric‐Gated Ion‐Gel Transistor for Neuromorphic Tactile Sensing and Human Activity Recognition

Advanced Materials Hanseong Cho, Seoyeon Park, Youngmin Lee et al. Jul 01, 2026 DOI: 10.1002/adma.202520540

ABSTRACT Wearable and flexible neuromorphic devices capable of accurately emulating synaptic behaviors while autonomously responding to mechanical stimuli hold great promise for intelligent sensing and bio‐inspired computing. Here, we present a fully flexible synaptic device in which a graphene‐channel ion‐gel‐gated transistor (g‐IGT) fabricated on a plastic substrate is directly driven by a poly(vinylidene fluoride‐co‐trifluoroethylene)‐based triboelectric nanogenerator (TENG), enabling self‐powered tactile sensing and analog weight storage. The device emulates the multistore memory hierarchy through sensory–short‐term–long‐term memory transitions, characterized by synaptic decay times of ∼70 ms (sensory), 0.2–0.45 s (short‐term), and >2.0 s (long‐term). Furthermore, rate‐coded learning is demonstrated through spike‐rate‐dependent plasticity, enabling frequency‐selective potentiation and depression. When the experimentally measured weight‐update profiles are implemented in a single‐layer perceptron for human activity recognition, the neural network system achieves >88% classification accuracy, even under 1.1 MPa bending stress. Furthermore, the network system maintains relatively stable performance (>75%) even under the extreme environment with a high noise level. These results establish the TENG‐driven g‐IGT as a viable route toward mechanically compliant, battery‐free neuromorphic platforms capable of sensing, learning, and adapting in situ.

Proximal labeling of the Golgi secretome reveals fat body–derived humoral factors in Drosophila disc regeneration

Journal of Biological Chemistry Yutaka Yoshida, Soshiro Kashio, Masayuki Miura Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113198

Efficacy of perioperative esketamine on postoperative recovery in patients with breast cancer undergoing modified radical mastectomy: A systematic review and meta-analysis.

Journal of Clinical Oncology Melisha Koirala, Aakash Pandit Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.54

54 Background: Modified radical mastectomy (MRM) causes significant acute postoperative and potential chronic pain. Esketamine offers potent analgesia with fewer side effects than racemic ketamine, though its recovery impact varies by dosing. This study evaluated esketamine's efficacy on pain, recovery quality, and efficiency in MRM. Methods: A systematic review and meta-analysis of RCTs compared perioperative esketamine to placebo/control in MRM. Primary outcomes were 24-hour Visual Analogue Scale (VAS) pain and Day-1 Quality of Recovery-15 (QoR-15). Secondary outcomes: rescue analgesia, extubation, and PACU stay. Random-effects models and subgroup analyses (bolus vs. infusion; dosing) were utilized to investigate heterogeneity. Results: Nine RCTs (n=749) were included. Esketamine significantly reduced 24-hour VAS scores (WMD -0.85; 95% CI -1.03 to -0.66). Stratification revealed this benefit was driven exclusively by continuous infusion (WMD -1.07; 95% CI -1.20 to -0.94; I 2 =0%), whereas single-bolus administration showed no significant effect (WMD 0.01). Quality of recovery (QoR-15) improved significantly (WMD 8.01; 95% CI 5.95 to 10.08), with greater benefits observed in low-dose protocols (WMD 11.50) compared to high-dose regimens. Esketamine reduced the risk of requiring rescue analgesia by 69% (RR 0.31; 95% CI 0.16 to 0.60). Regarding efficiency, esketamine did not delay extubation (WMD -0.16 min) after excluding trials with background dexmedetomidine confounding. PACU stay duration exhibited a dose-dependent divergence: low-dose regimens shortened stay (WMD -2.85 min; P=0.02), whereas high-dose/sedative combinations prolonged it (WMD 6.78 min; P<0.00001). Conclusions: Continuous intraoperative esketamine infusion provides robust analgesic efficacy and enhances quality of recovery in breast cancer surgery, whereas single-bolus dosing does not. Importantly, low-dose regimens improve recovery metrics without delaying extubation or PACU discharge. These findings support the integration of low-dose esketamine infusions into multimodal analgesic regimens for mastectomy.

How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia

Journal of Clinical Oncology Vincent Levy, Sylvie Chevret Jul 01, 2026 DOI: 10.1200/jco-25-03114

Flexible Organic Single Crystals with Unconventional Negative Photoconductivity for Intelligent Security Systems

Journal of the American Chemical Society Prodipta Samadder, Charanjeet Singh, Romy Garg et al. Jul 01, 2026 DOI: 10.1021/jacs.6c08011

Unlocking Photocatalytic CO <sub>2</sub> Conversion to Ethylene Glycol by Microdroplet‐Enabled Interfacial Electric Field

Angewandte Chemie International Edition Mengqiu Xu, Yutong Wang, Ran Tang et al. Jul 01, 2026 DOI: 10.1002/anie.6306355

ABSTRACT The electrochemical carbon dioxide (CO 2 ) reduction features attractive potentials of carbon neutrality and chemical upgrading, while the types of products from photocatalysis or electrocatalysis still remain limited. The conversion of CO 2 into ethylene glycol, an important chemical that is typically produced by thermo‐catalytic process, has not been achieved by photocatalysis or electrocatalysis. Herein, we demonstrate a microdroplet‐enhanced photocatalytic strategy with a Pd‐TiO 2 catalyst, which allows for efficient conversion of CO 2 into ethylene glycol with high selectivity. The electro‐sprayed microdroplets provide a high interfacial electric field that facilitates deep reduction of CO 2 into *CH 3 , as well as generation of reactive *OH intermediates to form CH 3 OH. The in situ formed CH 3 OH is further photo‐catalytically activated to cleave a C−H bond to *CH 2 OH, followed by the C−C coupling to produce ethylene glycol. Under 1‐sun illumination, the electro‐sprayed microdroplets and Pd‐TiO 2 catalyst exhibited a high CO 2 ‐to‐ethylene glycol conversion rate of 2985 µmol L −1 h −1 , which significantly outperformed those by only photocatalysis or only electro‐sprayed microdroplets, revealing the capability of combining multiple energy fields for tuning reaction pathways and advancing green synthesis.

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL

Blood Sairah Ahmed, Alejandro Martin Garcia-Sancho, Juan Luis Reguera-Ortega et al. Jul 01, 2026 DOI: 10.1182/blood.2026034327

In the TRANSCEND FL primary analysis, lisocabtagene maraleucel (liso-cel) showed high response rates and favorable safety in patients with relapsed/refractory (R/R) follicular lymphoma (FL). Longer follow-up is needed to assess remission durability and long-term or late-onset toxicities. Here, we report 3-year follow-up results (median [range] on-study follow-up, 41.5 months [0.3‒54.0]) in patients with third-line or later (3L+) FL. Patients had R/R FL after ≥2 prior lines of combination systemic therapy, including an anti-CD20 antibody and an alkylator. A total of 107 patients received liso-cel and 103 were efficacy evaluable, with overall and complete response rates (95% CI) per independent review committee of 97% (92‒99) and 94% (88‒98), respectively. Medians were not reached for all time-to-event outcomes; estimated 36-month (95% CI) rates for duration of response, progression-free survival, time free from next treatment, and overall survival were 70% (60‒78), 68% (58‒76), 75% (70‒80), and 86% (78‒92), respectively. Response rates and 36-month time-to-event rates were consistent in high-risk subgroups, including patients with disease progression within 24 months of starting first-line immunochemotherapy, bulky disease, or double-refractory status. Longitudinal safety analyses showed decreasing grade ≥3 cytopenias and hypogammaglobulinemia (immunoglobulin G &amp;lt;500 mg/dL), with use of supportive care (transfusions, growth factors, intravenous immunoglobulin) mostly limited to the 3 months after infusion, and consistently low incidences of grade ≥3 infections in short- and long-term periods. At 3-year follow-up, a single liso-cel infusion delivered durable efficacy and high survival, including in high-risk subgroups, alongside a favorable long-term safety profile in patients with 3L+ FL. Clinicaltrials.gov: NCT04245839.

Global metabolomic profiling of serum biomarkers in women with polycystic ovary syndrome

Scientific Reports Jalpa Patel, Hiral Chaudhary, Sonal Panchal et al. Jul 01, 2026 DOI: 10.1038/s41598-026-60249-8

Novel drug targets in 2025

Nature Reviews Drug Discovery Sorin Avram, Liliana Halip, Ramona Curpan et al. Jul 01, 2026 DOI: 10.1038/d41573-026-00102-9

Clinical implementation of multi-cancer early detection tests: can we find a path forward?

Nature Reviews Clinical Oncology Ariadna Tibau, Aaron S. Kesselheim Jul 01, 2026 DOI: 10.1038/s41571-026-01158-7

Targeted enzyme discovery using metal-coordination mining

Nature Ioannis Kipouros, Michelle C. Y. Chang Jul 01, 2026 DOI: 10.1038/s41586-026-10716-z

Asymmetric Electronic Modulation Accelerating Proton‐Coupled Electron Transfer and CO <sub>2</sub> Reduction at Strongly Negative Potentials

Advanced Materials Ruina Li, Haoyu Long, Guoen Tang et al. Jul 01, 2026 DOI: 10.1002/adma.73766

ABSTRACT Electrochemical CO 2 reduction to value‐added chemicals offers a sustainable route toward carbon neutrality under mild conditions. Yet, it faces an intrinsic proton‐electron imbalance at strongly negative potentials, where the hydrogen evolution reaction (HER) dominates, depletes interfacial protons, and severely compromises CO 2 reduction selectivity. Here, we report an asymmetric Ni–Fe dual‐atom electrocatalyst that restores efficient proton‐coupled electron transfer (PCET) through cross‐site synergy. Electron migration from Fe to Ni establishes a local asymmetric electric field that enhances CO 2 adsorption and induces molecular bending at Ni sites, thereby weakening the C═O bond. Simultaneously, electron‐deficient Fe sites exhibit moderated H adsorption, suppressing HER while serving as transient proton reservoirs for adjacent Ni centers. This spatially separated yet temporally synchronized PCET pathway accelerates the rate‐determining CO 2 → COOH step and sustains efficient CO 2 ‐to‐CO conversion under deeply cathodic conditions. Consequently, the Ni─Fe dual‐atom electrocatalyst maintains CO selectivity exceeding 95% across a wide potential window from −0.9 to −1.4 V and reaches 99.1% at −1.2 V, markedly outperforming monometallic analogues that exhibit volcano‐type selectivity decay due to unbalanced PCET‐HER kinetics. This work highlights asymmetric electronic modulation as an effective strategy to resolve the intrinsic PCET‐HER selectivity conflict in CO 2 reduction.

Photothermal Sensitive Nano Heterojunction Triggering Ferroptosis and PANoptosis for Improving Tumor Immunotherapy

Advanced Materials Zongyan He, Xinyue Shao, Xiaolong Feng et al. Jul 01, 2026 DOI: 10.1002/adma.73503

ABSTRACT Photodynamic therapy (PDT) and photothermal therapy (PTT) demonstrate considerable clinical potential in tumor treatment by inducing apoptosis through the generation of reactive oxygen species (ROS) and hyperthermia. However, their therapeutic efficacy is hampered by the inherent resistance of tumor cells to apoptotic pathways. Immunogenic cell death (ICD) modalities, such as ferroptosis and PANoptosis, circumvent this resistance by eliciting robust anti‐tumor immune responses. Nevertheless, conventional ICD inducers are plagued by suboptimal pharmacokinetics and dose‐dependent toxicity, necessitating the highly efficient, non‐toxic ferroptosis/PANoptosis activators. Herein, a bismuth‐based photothermal‐sensitive nano‐heterojunction (Bi 2 S 3 @Bi 2 Se 3 @Se‐PEG, BSSP) synergistically triggering ferroptosis and PANoptosis is constructed. BSSP minimizes charge recombination while enhancing catalytic activity. The pyroelectric properties of Bi 2 S 3 /Bi 2 Se 3 and selenium's photo/thermal sensitivity cooperatively amplify ROS production and achieve superior photothermal conversion efficiency to enhance both PDT and PTT. In the murine 4T1 breast cancer model, BSSP combined with near‐infrared irradiation significantly suppresses primary tumor growth, inhibits distal tumor proliferation, and attenuates pulmonary metastasis. Moreover, BSSP remodels the immunosuppressive tumor microenvironment with excellent biocompatibility. The photothermally responsive nano‐heterojunction presents an innovative paradigm for the simultaneous activation of ferroptosis and PANoptosis via combined PDT and PTT, offering new avenues for semiconductor‐based cancer immunotherapy.

Correction: Colchicine inhibits vascular calcification by suppressing inflammasome activation through the enhancement of the Sirt2-PP2Ac signaling pathway

Journal of Biological Chemistry Shu Yang, Heming Huang, Kewei Jiang et al. Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113171